Clinical performance study of breast cancer prognostic diagnosticsGenesWell™ BCT in Korean patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer

Samsung Medical Center0 个研究点目标入组 500 人开始时间: 待定最近更新: 2019年10月7日

试验速览

暂无简介。

•1.1. Selection criteria
•1.1.1. Criteria for Selection of Sample Providers
•1) hormone receptor positive (ER+ and/or PR+)
•2) Human epidermal growth factor receptor type2 negative (HER2-)
•3) pN0 or pN1 is applicable
•4) Female patients
•1.1.2. Criteria for selecting remaining samples
•1) Residual samples containing the collected tissue with paraffin (FFPE residual samples)
•2) In case pathological samples that are not obstructed in future care are stored

•1.1.1. Exclusion Criteria for Sample Providers
•1) For hormone receptor negative (ER- and PR-)
•2) Human epidermal growth factor receptor type2 (HER2+)
•3) pN2, or pN3 is applicable
•1.1.2. Exclusion Criteria for Residual Specimens
•1) Remaining samples not covered with paraffin (non-FFPE residual samples)
•2) Pathologists have determined that the condition of the FFPE block is not available for clinical trials in tissue and pathology

发起方